We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.04B
AUM Growth
-$325M
Cap. Flow
-$209M
Cap. Flow %
-2.31%
Top 10 Hldgs %
81.82%
Holding
98
New
4
Increased
11
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$78.4M
2
PCVX icon
Vaxcyte
PCVX
+$47.3M
3
INSM icon
Insmed
INSM
+$28.6M
4
IMCR icon
Immunocore
IMCR
+$24.2M
5
CELC icon
Celcuity
CELC
+$17.9M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$171M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
3
KRYS icon
Krystal Biotech
KRYS
+$26.6M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$26.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.87%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.45B
$7.13M 0.08%
670,431
– –
DYN icon
52
Dyne Therapeutics
DYN
$4.15B
$7.03M 0.08%
672,096
– –
KALA icon
53
KALA BIO
KALA
$12.5M
$6.89M 0.08%
24,038
– –
DSGN icon
54
Design Therapeutics
DSGN
$751M
$6.73M 0.07%
1,743,725
– –
GPCR icon
55
Structure Therapeutics
GPCR
$3.37B
$6.26M 0.07%
361,565
– –
TSHA icon
56
Taysha Gene Therapies
TSHA
$1.61B
$5.57M 0.06%
4,004,756
– –
RGLS
57
DELISTED
Regulus Therapeutics
RGLS
$4.71M 0.05%
+2,694,044
New +$3.55M
IGMS
58
DELISTED
IGM Biosciences
IGMS
$4.71M 0.05%
4,095,257
+953
+0% +$1.77K
NTLA icon
59
Intellia Therapeutics
NTLA
$1.51B
$4.58M 0.05%
644,116
– –
CLDX icon
60
Celldex Therapeutics
CLDX
$2.94B
$4.49M 0.05%
247,644
– –
SION
61
Sionna Therapeutics
SION
$2.02B
$4.18M 0.05%
+400,000
New +$6.54M
BNTX icon
62
BioNTech
BNTX
$23.5B
$4.1M 0.05%
45,031
– –
TCRX icon
63
TScan Therapeutics
TCRX
$48.5M
$3.84M 0.04%
2,784,792
– –
IRON icon
64
Disc Medicine
IRON
$2.81B
$3.82M 0.04%
77,050
– –
VIR icon
65
Vir Biotechnology
VIR
$1.46B
$3.52M 0.04%
542,539
-542,000
-50% -$4.82M
SANA icon
66
Sana Biotechnology
SANA
$882M
$3.41M 0.04%
2,030,949
-350,000
-15% -$978K
SGMT icon
67
Sagimet Biosciences
SGMT
$435M
$3.11M 0.03%
952,996
– –
RLAY icon
68
Relay Therapeutics
RLAY
$4B
$3.04M 0.03%
1,160,117
– –
WVE icon
69
Wave Life Sciences
WVE
$1.12B
$2.78M 0.03%
344,063
– –
FATE icon
70
Fate Therapeutics
FATE
$275M
$2.57M 0.03%
3,258,402
– –
SKYE icon
71
Skye Bioscience
SKYE
$21.6M
$2.31M 0.03%
1,450,638
– –
TARA icon
72
Protara Therapeutics
TARA
$214M
$2.29M 0.03%
536,832
– –
ELVN icon
73
Enliven Therapeutics
ELVN
$3.78B
$2.26M 0.03%
114,833
– –
CTNM
74
Contineum Therapeutics
CTNM
$538M
$2.18M 0.02%
312,500
– –
PRME icon
75
Prime Medicine
PRME
$547M
$2.05M 0.02%
1,028,466
– –
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Baker Bros. Advisors held 98 positions worth $9.04B, down 3.5% from $9.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q1 2025 filing shows 4 new, 11 increased, 16 reduced and 9 closed positions. Its largest new stake was Verona Pharma: 223,843 shares worth $14.2M. The largest sale was BeOne Medicines Ltd, an estimated $171M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2025 buy was Verona Pharma: 223,843 shares worth $14.2M.
  • Baker Bros. Advisors added most to Immunovant in Q1 2025, an estimated $78.4M increase.
  • Baker Bros. Advisors's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $171M.
  • Baker Bros. Advisors fully exited Krystal Biotech in Q1 2025, selling an estimated $26.6M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $9.04B portfolio in Q1 2025.
  • Baker Bros. Advisors opened 4 new positions and closed 9 in Q1 2025.
  • Baker Bros. Advisors's portfolio value fell 3.5% quarter-over-quarter to $9.04B.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.